UBS Group’s Aptevo Therapeutics APVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.24K | Sell |
730
-2,715
| -79% | -$13.1K | ﹤0.01% | 9216 |
|
|
2026
Q1 | $14.7K | Buy |
3,445
+3,275
| +1,926% | +$22.4K | ﹤0.01% | 8154 |
|
|
2025
Q4 | $1.6K | Sell |
170
-145
| -46% | -$3.45K | ﹤0.01% | 9524 |
|
|
2025
Q3 | $8.23K | Buy |
+315
| New | +$12.7K | ﹤0.01% | 8674 |
|
|
2025
Q1 | – | Sell |
-2
| Closed | -$3.38K | – | 10200 |
|
|
2024
Q4 | $3.38K | Buy |
+2
| New | +$5.75K | ﹤0.01% | 8887 |
|
|
2024
Q3 | – | Sell |
-9
| Closed | -$41.4K | – | 9483 |
|
|
2024
Q2 | $35.5K | Buy |
+9
| New | +$134K | ﹤0.01% | 6957 |
|
|
2024
Q1 | – | Hold |
0
| – | -$1 | – | 9261 |
|
|
2023
Q4 | – | Hold |
0
| – | – | – | 9198 |
|
|
2023
Q3 | – | Hold |
0
| – | – | – | 9087 |
|
|
2023
Q1 | – | Hold |
0
| – | -$3.32K | – | 9572 |
|
|
2022
Q4 | – | Hold |
0
| – | – | – | 9526 |
|
|
2022
Q3 | – | Hold |
0
| – | – | – | 9918 |
|
|
2022
Q2 | – | Hold |
0
| – | – | – | 9030 |
|
|
2022
Q1 | – | Hold |
0
| – | -$25K | – | 10209 |
|
|
2021
Q4 | – | Hold |
0
| – | – | – | 7578 |
|
|
2021
Q3 | – | Hold |
0
| – | -$41K | – | 9497 |
|
|
2021
Q2 | – | Hold |
0
| – | – | – | 6603 |
|
|
2021
Q1 | – | Hold |
0
| – | -$11K | – | 8964 |
|
|
2020
Q4 | – | Hold |
0
| – | – | – | 7395 |
|
|
2020
Q3 | – | Hold |
0
| – | – | – | 5433 |
|
|
2020
Q2 | – | Hold |
0
| – | – | – | 5439 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 5946 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 5928 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 5890 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 5486 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 5658 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 6360 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 5091 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 4986 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 4970 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 4925 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 6444 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 5472 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 5361 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 6228 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 5991 |
|
Other funds holding APVO
GCP
SS
DB
UBS Group's APVO Position: Q2 2026 in Review
UBS Group reduced its Aptevo Therapeutics (APVO) stake by 79% in Q2 2026, selling an estimated $13.1K and leaving 730 shares worth $3.24K. The position accounts for ﹤0.01% of the portfolio, ranked #9216.
UBS Group first reported a position in APVO in Q2 2024 and has held it in 6 quarters since. The position peaked at $35.5K in Q2 2024. 9 funds tracked by Wall St. Rank hold APVO as of Q2 2026.
- UBS Group held 730 shares of Aptevo Therapeutics worth $3.24K as of Q2 2026.
- UBS Group sold 2,715 Aptevo Therapeutics shares in Q2 2026, an estimated $13.1K.
- Aptevo Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9216 holding.
- UBS Group first reported a position in Aptevo Therapeutics in Q2 2024 and has held it in 6 quarters since.
- UBS Group's Aptevo Therapeutics position peaked at $35.5K in Q2 2024.
- 9 funds tracked by Wall St. Rank held Aptevo Therapeutics as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.